PRESS RELEASE | 08/04/2026
Hict is proud to announce its participation in COMPASS (Cardio-Oncology Multidisciplinary Patient ASsistance Solution), a large-scale European research initiative aiming to transform cardio-oncology care through artificial intelligence and digital innovation.
As cancer survival continues to improve, cardiovascular complications linked to cancer treatments have become an increasing concern. Around one in four anticancer medicines carries warnings related to cardiac or vascular side effects, creating long-term risks for patients and added pressure on healthcare systems. Early detection, personalised prevention strategies and digitally enabled care pathways are now critical to improving outcomes.
The COMPASS project responds directly to this challenge by developing integrated, AI-supported solutions that enable better prediction, monitoring and management of cardiotoxicity across the entire cancer care pathway.
Within the COMPASS consortium, Hict contributes its expertise in applied artificial intelligence and digital health, participating in work packages focused on:
Through these activities, Hict supports the development of interoperable, scalable solutions that help clinicians make safer and more personalised decisions while empowering patients with better visibility of their heart health during and after cancer treatment.
The COMPASS consortium officially launched the project during a two-day kick-off meeting held on 26–27 March 2026 in London, hosted by King’s College London at St Thomas’ Hospital. The meeting brought together clinical, academic and industrial partners to align on objectives, work plans and collaboration frameworks for the coming years.
Funded by the Innovative Health Initiative (IHI) and coordinated academically by King’s College London and industrially by GE HealthCare, COMPASS unites hospitals, universities, research centres, MedTech and digital health companies, SMEs and patient organisations. By combining public funding with industry expertise, the project aims to accelerate innovation and translate research outcomes into real-world healthcare solutions.
Over the next five years, COMPASS will develop a comprehensive, patient-focused cardio-oncology care pathway that spans cancer diagnosis, treatment and long-term survivorship. The project will explore early indicators of cardiovascular stress using biomarkers, advanced imaging and continuous monitoring technologies, supported by AI-driven predictive models.
A key outcome of COMPASS is the development of an interoperable Clinical Decision Support System (CDSS), designed to integrate diverse clinical and monitoring data and support more timely, personalised and safer care decisions. Continuous monitoring and user-friendly digital tools will also help patients better understand and manage their cardiovascular risks throughout their cancer journey.
Beyond technology, COMPASS promotes closer collaboration between cardiologists, oncologists and other healthcare professionals, contributing to more integrated and sustainable care pathways across Europe. Patient perspectives are central to the project, with dedicated efforts to develop clear educational materials and digital tools that ensure innovations are accessible, meaningful and aligned with real patient needs.
Through its participation in COMPASS, Hict reinforces its commitment to applying AI in impactful, clinically relevant ways, supporting more proactive, personalised and sustainable healthcare solutions for patients living with and beyond cancer.
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement 101253264. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe, and ECG Médica SL (Ascires).
Notre expertise pour votre entreprise ?
Découvrez notre offre!
